Who is sponsoring NCT03935074?

NCT03935074 is sponsored by Istanbul University - Cerrahpasa.

What drugs are being tested in NCT03935074?

Interventions in NCT03935074: intra-arterial administration of melphalan.

What condition does NCT03935074 study?

NCT03935074 studies Retinoblastoma.

Is NCT03935074 still recruiting?

NCT03935074 is currently completed. Last updated 6 May 2019.

Last reviewed 2019-05-06 · How we verify

NCT03935074

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey

Completed Last updated 6 May 2019

What this trial tests

trial testing intra-arterial administration of melphalan in Retinoblastoma in 30 participants. Completed in 30 November 2016.

Timeline

30 August 2016

Primary endpoint
30 November 2016

30 November 2016

Quick facts

Lead sponsor	Istanbul University - Cerrahpasa
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	30 August 2016
Primary completion	30 November 2016
Estimated completion	30 November 2016
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

intra-arterial administration of melphalan — full drug profile →

Conditions studied

Retinoblastoma — all drugs for Retinoblastoma →

Sponsor

Istanbul University - Cerrahpasa

Who can join

Adults 5 Months to 7, any sex, with Retinoblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute. The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Retinoblastoma: An update on genetic origin, classification, conventional to next-generation treatment strategies.
Pareek A, Kumar D, Pareek A, Gupta MM, et al · · 2024 · cited 10× · PMID 38975183 · DOI 10.1016/j.heliyon.2024.e32844

Verify or expand the search:

Other recruiting trials for Retinoblastoma

Currently open trials in the same condition.

NCT06725173 — Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra- · recruiting
NCT06972602 — High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed · EARLY_PHASE1 · recruiting
NCT06424301 — Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma · EARLY_PHASE1 · recruiting
NCT06367530 — Trilateral Retinoblastoma: Incidence and Outcomes · recruiting
NCT05650749 — GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma · Phase 1 · recruiting

Other Istanbul University - Cerrahpasa trials

Trials by the same sponsor.

NCT07588685 — Validity and Reliability of the Turkish Form of the Enjoyment of Physical Activity Scale-8 in Geriatrics With Minimal Co · not yet recruiting
NCT07370025 — The Effect of Lullaby During Bath Time on Mother-Infant Bonding, Postpartum Depression, and Parental Self-Efficacy in In · NA · not yet recruiting
NCT07378449 — The Effect of Hand Exercise Hoops on Labour Pain · NA · not yet recruiting
NCT07293000 — Evaluating Two Nursing Interventions to Prevent Urinary Retention After Spinal Anesthesia · NA · not yet recruiting
NCT07562880 — Validity and Reliability of the Exercise-Related Health Beliefs Attitude Scale in Geriatric Individuals · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03935074 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Istanbul University - Cerrahpasa
Last refreshed: 6 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03935074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing